Yunxia Zhu

Yunxia Zhu

Auto-generated profile, based on publicly available information

Yunxia Zhu

Departments of Obstetrics, Beijing Youan Hospital, Capital Medical University, 100069 Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2020 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
LCLingzhi Chang
Lingzhi Chang
MWMing - Wang
Ming - Wang
HLHaixia Liu
Haixia Liu
QMQinghua Meng
Qinghua Meng
HYHongwei Yu
Hongwei Yu
YZYunxia Zhu
Yunxia Zhu
Background: Limited data exists regarding the pregnancy and infant outcomes of Acute Fatty Liver of Pregnancy (AFLP). Methods: Retrospectively collected mothers with AFLP and mothers without AFLP in our center from 1/2008 to 6/2018. The primary assessment was to analyze and compare the frequency of negative maternal and fetal outcomes. The secondary assessment was to investigate the role of intrauterine balloon tamponade in reducing negative maternal outcomes. Results: Compared to 220 matched mothers, 55 AFLP mothers were younger (P < 0.001), with fewer pregnancies (P = 0.033), complicated with more pregnancy induced hypertension (P < 0.001), twins(P = 0.002), fetal growth restriction (P = 0.044) and male fetus (P < 0.001). 3 (5.5%) of AFLP patients were diagnosed in the postpartum period. Mean gestational week of AFLP diagnosis was 35.25 ± 5.80 weeks. Jaundice (89.1%), nausea or vomiting (58.2%), anorexia (49.1%), fatigue (45.5%) and polydipsia (30.9%) were the main prodromal symptoms. The median duration from diagnosis to delivery was 1.55 ± 4.62 days and 75% (39/52) pregnancy were terminated the pregnancy at the day of diagnosis. 78.8% (41/52) patients received cesarean section, 53.6% (22/41) of which received preventive plasma transfusion before surgery and no one received artificial liver support during the treatment. In comparison, higher frequency of 16 maternal complications, severe negative outcomes (27.3% vs. 0.9%) and newborn asphyxia (24.6% vs.0.9%) were observed in AFLP population. 3 mothers (mortality rates: 5.5%) died of multiple organ system failure and 6 fetus/infants (death rates: 9.8%) died of distress. When compared to those without negative outcomes, patients with negative fetal outcomes were younger (P = 0.042), had more singleton rates (p = 0.041), increased mean value of ALT(P = 0.011) and T-Bilirubin (P = 0.014), decreased prothrombin activity (P = 0.011). Although no statistical significance for the small sample size, there were less refractory postpartum hemorrhage (0% vs.31.3%), hysterectomy (0% vs.12.5%), negative maternal outcomes (16.7% vs.56.3%) in patients underwent intrauterine balloon tamponade when postpartum hemorrhage exceeded 500 ml. Conclusions: Several symptoms were found to be the main prodromal symptoms of AFLP. Higher frequency of adverse maternal and fetal outcomes was observed in mothers with AFLP than mothers without AFLP. We found five potential risk factors of negative fetal outcomes.

1 November 2019 in Medicine
Verified
Journal Article
Open access
MWMing Wang
Ming Wang
YHYing Hou
Ying Hou
SMShi-Hui Meng
Shi-Hui Meng
BYBo Yang
Bo Yang
PYPing Yang
Ping Yang
YZYunxia Zhu
Yunxia Zhu
Alanine transaminase (ALT) abnormalities are common in chronic hepatitis B (CHB) carriers during postpartum period. Disturbances in cytokines are considered to be associated with hepatitis Flares. There are limited data on cytokines changes in HBeAg positive patients with ALT abnormalities.This is an observational study. Pregnant patients with hepatitis B e-antigen (HBeAg) positive were enrolled from January 2014 to September 2018. Patients were assigned into three groups based on ALT levels in postpartum 6 to 8 weeks: ALT in normal range, ALT in 1 to 2-fold upper limits of normal (ULN) and ALT >2-fold ULN. Serum cytokines, ratios of regulatory T cells, and the concentration of cortisol were collected and compared among the three groups.Of the 135 mothers enrolled, 80.7% (109/135) completed the postpartum 6-week study. 13.8% (15/109) patients had postpartum ALT higher than 2∗ULN, 27.5% (30/109) patients had ALT in 1 to 2∗ULN and 58.7% (64/109) patients had ALT in normal range. Compared to control group, patients with ALT >2∗ULN had a higher IL-10 level (P < .05). No differences of IL-10 levels were found in the comparison of other inter comparison among three groups. No differences were found in the levels of other collected serum cytokines, cortisol, and regulatory T cells among three groups. On multivariate analysis, abnormal IL-10 level was independent risk factor for postpartum ALT elevating >2∗ULN. At the same time, the incidence of postpartum ALT elevated >2∗ULN were higher in patients with abnormal elevation IL-10 level than in patients with normal IL-10 level (14/68 vs 1/41,P = .008).CHB patients with postpartum ALT abnormalities show higher IL-10 level and postpartum ALT abnormalities were mainly occurred in patients with abnormal IL-10 level. IL-10 may be an underlying predictor and treatment target of hepatitis B, and further studies are needed.

16 July 2021 in Ginekologia Polska
Verified
Journal Article
Closed access
PDF file
CZChong Zhang
Chong Zhang
HWHong Wei
Hong Wei
YZYun-Xia Zhu
Yun-Xia Zhu
Objectives: The aim of this study was to investigate adverse pregnancy outcomes (APOs) and mother-to-child transmission (MTCT) of intrahepatic cholestasis in pregnancy (ICP) in hepatitis B virus infection (HBV) patients. Material and methods: We performed a retrospective study at Beijing Youan Hospital in China from January 2010 through May 2017. A total of 232 patients were enrolled, including 106 HBV-infected ICP patients (Group H + C), 20 ICP patients (Group C) and 106 HBV-infected patients (Group H). Characteristics, APOs and MTCT rate of HBV were compared between groups. Group H + C was subdivided into 3 groups according to total bile acid (TBA) values and gestational age at diagnosis (GA). APOs were also compared within Group H + C according to TBA values and GA. Results: There was no difference in live birth delivery mode and APOs between Groups H + C and C. Compared with Groups H, no difference was in live birth and MTCT rates of HBV. However, cesarean section delivery and APOs rates were higher in Group H+C (p < 0.05). Compared with Group H, adverse maternal outcomes such as postpartum hemorrhage and premature birth were more likely to occur in Group H + C (p < 0.001). Adverse fetal outcomes, the proportions of amniotic fluid reaching III degrees (AFIII), NICU admission, neonatal asphyxia and SGA were significantly higher among Group H + C than Group H (p < 0.05). Contamination of the AFIII rate increased with increasing TBA (p < 0.05). The rate of preterm birth and small for gestational age (SGA) was more common in GA 28–32 w compared with GA < 28 w and > 33 w (p < 0.01). Conclusions: H + C patients had more APOs than HBV patients, but the difference was not significant when compared with ICP patients. Although we did not find any difference in MTCT rate between H + C and HBV patients, active treatment to prevent neonatal asphyxia and HBV infection should be considered. Therefore, it is necessary to emphasize maternal and fetal monitoring during pregnancy and delivery. Objectives: The aim of this study was to investigate adverse pregnancy outcomes (APOs) and mother-to-child transmission (MTCT) of intrahepatic cholestasis in pregnancy (ICP) in hepatitis B virus infection (HBV) patients. Material and methods: We performed a retrospective study at Beijing Youan Hospital in China from January 2010 through May 2017. A total of 232 patients were enrolled, including 106 HBV-infected ICP patients (Group H + C), 20 ICP patients (Group C) and 106 HBV-infected patients (Group H). Characteristics, APOs and MTCT rate of HBV were compared between groups. Group H + C was subdivided into 3 groups according to total bile acid (TBA) values and gestational age at diagnosis (GA). APOs were also compared within Group H + C according to TBA values and GA. Results: There was no difference in live birth delivery mode and APOs between Groups H + C and C. Compared with Groups H, no difference was in live birth and MTCT rates of HBV. However, cesarean section delivery and APOs rates were higher in Group H+C (p < 0.05). Compared with Group H, adverse maternal outcomes such as postpartum hemorrhage and premature birth were more likely to occur in Group H + C (p < 0.001). Adverse fetal outcomes, the proportions of amniotic fluid reaching III degrees (AFIII), NICU admission, neonatal asphyxia and SGA were significantly higher among Group H + C than Group H (p < 0.05). Contamination of the AFIII rate increased with increasing TBA (p < 0.05). The rate of preterm birth and small for gestational age (SGA) was more common in GA 28–32 w compared with GA < 28 w and > 33 w (p < 0.01). Conclusions: H + C patients had more APOs than HBV patients, but the difference was not significant when compared with ICP patients. Although we did not find any difference in MTCT rate between H + C and HBV patients, active treatment to prevent neonatal asphyxia and HBV infection should be considered. Therefore, it is necessary to emphasize maternal and fetal monitoring during pregnancy and delivery.

18 February 2024 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
CZChong Zhang
Chong Zhang
HWHong Wei
Hong Wei
ZZZhiqiang Zhao
Zhiqiang Zhao
YZYunxia Zhu
Yunxia Zhu
Background: We conducted this study to investigate adverse pregnancy outcomes of hepatitis B virus infection coexistng with intrahepatic cholestasis in pregnant women, along with identifying associated risk factors. Methods: We retrospectively collected study data from Beijing Youan Hospital in China spanning January 2014 to December 2021. The study included 220 patients, divided into two groups: Group I consisted of 110 patients with hepatitis B virus infection and intrahepatic cholestasis during pregnancy, while Group II comprised 110 patients with hepatitis B virus infection alone. Maternal demographics, laboratory values, obstetric complications, and adverse pregnancy outcomes were collected and analyzed between Groups I and II. To investigate the features of hepatitis B virus infection with intrahepatic cholestasis in pregnancy patients further, we also evaluated risk factors of adverse pregnancy outcomes in Group I. Results: Adverse pregnancy outcomes, including preterm birth (<37 weeks (w)), postpartum hemorrhage, meconium-stained amniotic fluid, neonatal asphyxia, neonate intensive care unit admission and small for gestational age rates were significantly increased for Group I compared with Group II (p < 0.05). In hepatitis B virus infection patients with intrahepatic cholestasis during pregnancy, elevated total serum bile acids independently correlated with six adverse pregnancy outcomes. Conclusions: Pregnant patients with both hepatitis B virus infection and intrahepatic cholestasis experienced a higher occurrence of adverse pregnancy outcomes compared to those with Hepatitis B virus infection alone. Total serum bile acids were an independent risk factor for adverse pregnancy outcomes in Hepatitis B virus infection with intrahepatic cholestasis during pregnancy. Clinical Trial Registration: The study was registered with https://classic.clinicaltrials.gov/ (no.: zx10201201).